For research use only. Not for therapeutic Use.
Lenalidomide-Br (Cat No.:I017892) is an analog of the cereblon (CRBN) ligand lenalidomide, specifically designed for the recruitment of the CRBN protein in the context of targeted protein degradation. It functions by acting as a ligand for E3 ubiquitin ligase. Lenalidomide-Br can be linked to a ligand for a specific protein of interest through a linker, forming proteolysis-targeting chimeras (PROTACs). An example of such a PROTAC is the STAT3 degrader SD-36 (HY-129602), which utilizes lenalidomide-Br to recruit CRBN and target STAT3 for degradation, potentially offering therapeutic benefits in cancer treatment.
| Catalog Number | I017892 |
| CAS Number | 2093387-36-9 |
| Molecular Formula | C₁₃H₁₁BrN₂O₃ |
| Purity | ≥95% |
| Target | Ligands for E3 Ligase |
| IUPAC Name | 3-(7-bromo-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione |
| InChI | InChI=1S/C13H11BrN2O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6H2,(H,15,17,18) |
| InChIKey | SCZFMUWTABGOGF-UHFFFAOYSA-N |
| SMILES | C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3Br |
| Reference | [1]. Bai L, et al. A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. Cancer Cell. 2019 Nov 11;36(5):498-511.e17.<br>[2]. Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61(2):462-481. |
